论文部分内容阅读
目的 研究乙型肝炎表面抗原 (HBsAg)作为肿瘤相关抗原用于肿瘤免疫基因治疗的可能性。方法 以 1× 10 6的编码HBsAg的重组腺病毒载体转染的DC(DC HBsAg)、编码增强型绿色荧光蛋白的重组腺病毒载体转染的DC(DC EGFP)、DC以及等体积的 1×PBS静脉免疫B6小鼠 2次 ,每次间隔 1周。于最后一次免疫 1周后 ,每只小鼠皮下接种 7× 10 5B16 HBsAg或等量的B16黑色素瘤细胞。观察各免疫组小鼠皮下肿瘤的生长情况。同法以 1× 10 6的DC HBsAg和DC EGFP、1μg重组HBsAg以及等体积 1×PBS免疫B6小鼠 ,亦于最后一次免疫 1周后 ,处死部分小鼠 ,检测血清中anti HBsAg抗体滴度 ,其余小鼠皮下接种等量的B16 HBsAg ,观察肿瘤生长情况。结果 DC HBsAg疫苗可以诱导出明显强于重组HBsAg疫苗的HBsAg特异的抗瘤免疫 ,但其诱导的体液免疫水平则明显低于重组HBsAg免疫。结论 HBsAg可以作为肿瘤免疫攻击的有效靶点用于抗肿瘤免疫。
Objective To study the possibility of hepatitis B surface antigen (HBsAg) as a tumor-associated antigen for tumor immunotherapy. Methods DC (DC HBsAg) transfected with 1 × 10 6 recombinant adenovirus vector encoding HBsAg, DC (DC EGFP) transfected with recombinant adenovirus vector encoding enhanced green fluorescent protein, DC, and an equal volume of 1 × B6 mice were intravenously immunized with PBS twice a week for 1 week. One week after the last immunization, each mouse was inoculated subcutaneously with 7 x 10 <5> B16 HBsAg or an equal amount of B16 melanoma cells. Observe the growth of subcutaneous tumor of mice in each immunization group. In the same method, B6 mice were immunized with 1 × 10 6 DC HBsAg and DC EGFP, 1 μg recombinant HBsAg and an equal volume of 1 × PBS. One week after the last immunization, some mice were sacrificed and the serum anti-HBsAg antibody titer , Other mice were inoculated subcutaneously with equal amount of B16 HBsAg to observe tumor growth. Results DC HBsAg vaccine induced HBsAg-specific anti-tumor immunity significantly stronger than that of recombinant HBsAg vaccine, but the level of humoral immunity induced by DC HBsAg vaccine was significantly lower than that of recombinant HBsAg vaccine. Conclusion HBsAg can be used as an effective target of tumor immune attack for anti-tumor immunity.